The newly-elected presidency team of Europe’s leading trade body has met to discuss the industry’s growing concern over the impact of proposed changes to pharmaceutical legislation in the region.
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has previously suggested the changes amount to a “sabotage” of the industry.
Lawmakers in Europe want to introduce a shorter period of exclusivity for novel medicines and other changes such as a voucher system for new antibiotics and a simpler regulatory submission process.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze